Citations 1
Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004
Palumbo, Antonio , Reece, Donna , Sonneveld, Pieter , Spencer, Andrew , Chanan‐Khan, Asher , Goldschmidt, Hartmut , Yeh, Howard, Schecter, Jordan M. , Qin, Xiang , Amin, Himal, Guckert, Mary, Ahmadi, Tahamtan , Dimopoulos, Meletios Α. , Orlowski, Robert Z.
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8609-TPS8609
